Purple day for epilepsy

The Epilepsy Support Group of Newcastle will be at Waratah Village Shopping Centre on March 26 raises funds and awareness and offering information on epilepsy in the community.

Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders

Aequus has been focused on expanding treatment options for neurological disorders through its current pipeline of development stage and in-licensed products. Aequus recognizes there has been an increased acceptance around the use of cannabinoids for epilepsy and MS in particular, however, uptake by the medical community has been limited by a need for a product that provides precise, controlled dose delivery.

Supernus to Present at Cowen Health Care Conference in March

Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company’s management will present an overview and update of the company and host investor meetings at the Cowen & Company 37th Annual Health Care Conference. A live webcast of the presentation can be accssed by visiting ‘Events & Presentations’ in the Investors Section on the Company’s website at www.supernus.com .

Epilepsy group seeks to enlist help to fight illness

The Epilepsy Foundation of Guyana on Monday hosted a discussion with several stakeholders to enlist their help to raise awareness about the illness and available treatment. The discussion coincided with the observance of International Epilepsy Day, under the theme ‘Putting Epilepsy in the Picture.’

Supernus Announces Issuance of Eighth U.S. Patent Protecting Trokendi XR

Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on January 31, 2017 of an eighth patent by the United States Patent and Trademark Office covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.